Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,154 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Combination Intervention Clear all
Recruiting Phase 2 Interventional

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

NCT05753306
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Interventions
Cisplatin, Computed Tomography, Gastrectomy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Paclitaxel, Hyperthermic Intraperitoneal Chemotherapy
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 29, 2026, 10:59 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

NCT06900595
View directory record Official record
Conditions
Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8, Stage IV Adrenal Cortical Carcinoma AJCC v8, Unresectable Adrenal Cortical Carcinoma
Interventions
Biospecimen Collection, Cabozantinib, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
81
States / cities
Phoenix, Arizona • La Jolla, California • Madera, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 29, 2026, 10:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer

NCT02089334
View directory record Official record
Conditions
Metastatic Renal Cell Cancer
Interventions
RX-0201
Drug
Lead sponsor
Rexahn Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Tucson, Arizona • Duarte, California • Albuquerque, New Mexico + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 29, 2026, 10:59 PM EDT
Recruiting Not applicable Interventional

Building Connections

NCT07091032
View directory record Official record
Conditions
Cancer Colorectal, Cancer Cervix, Depression, Anxiety, Obesity
Interventions
Treatment as Usual, Building Connections Intervention
Other · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 29, 2026, 10:59 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Gilbert, Arizona • Burbank, California • Corona, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Not applicable Interventional

Patient and Provider Interventions for Managing Osteoarthritis in Primary Care

NCT01435109
View directory record Official record
Conditions
Osteoarthritis
Interventions
Patient Behavioral Intervention for OA, Provider Intervention for OA, Combined Patient and Provider Interventions for OA
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Not applicable Interventional

Pain Relief Effects on Length of Labor

NCT01750099
View directory record Official record
Conditions
Labor Pain
Interventions
Combined Spinal-epidural, Continuous Lumbar epidural
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years to 44 Years · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 29, 2026, 10:59 PM EDT
Active, not recruiting Phase 1 Interventional

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01955499
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CLA and Vitamin D on Protein Turnover

NCT03115775
View directory record Official record
Conditions
Protein
Interventions
Conjugated linoleic acid, Vitamin D, Conjugated linoleic acid and Vitamin D, Corn oil (placebo)
Dietary Supplement · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Not applicable Interventional Results available

MedStar Health Type 2 Diabetes Pathway to Control

NCT02925312
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
Diabetes Pathway
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Not applicable Interventional Results available

Ankle-foot Orthoses for Peripheral Artery Disease

NCT02280200
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
AFO to improve outcomes
Device
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 29, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional Results available

STAT-STatin and Aspirin in Trauma

NCT02901067
View directory record Official record
Conditions
Wounds and Injuries, Venous Thromboembolism
Interventions
Aspirin and Rosuvastatin, Placebo (for Aspirin and Rosuvastatin)
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Not applicable Interventional

Treatment for Psychogenic Nonepileptic Seizures and Post-traumatic Stress Disorder Using Prolonged Exposure Therapy (PE) or Psychoeducation for PNES

NCT07344766
View directory record Official record
Conditions
Psychogenic Nonepileptic Seizures (PNESs), Post Traumatic Stress Disorder PTSD
Interventions
imaginal and in vivo exposure, psychoeducation for psychogenic nonepileptic seizures
Behavioral
Lead sponsor
Northeast Regional Epilepsy Group
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Phase 4 Interventional Results available

Low Level Laser Treatment and Breast Cancer Related Lymphedema

NCT00852930
View directory record Official record
Conditions
Lymphedema
Interventions
laser and MLD combined, laser alone, manual lymphatic drainage
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 29, 2026, 10:59 PM EDT
Not listed Phase 2 Interventional

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

NCT03668431
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Dabrafenib, Trametinib, PDR001
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 29, 2026, 10:59 PM EDT
Recruiting Not applicable Interventional

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

NCT05890677
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Surgical Intervention, Conservative Complex Physical Decongestion Therapy
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 10:59 PM EDT
Recruiting Phase 2 Interventional

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

NCT05873712
View directory record Official record
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lisocabtagene Maraleucel, Lymph Node Biopsy, Positron Emission Tomography, Zanubrutinib
Procedure · Drug · Biological
Lead sponsor
Aseel Alsouqi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 29, 2026, 10:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

NCT07421700
View directory record Official record
Conditions
Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
Interventions
PF-08634404, Enfortumab Vedotin
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
164
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 29, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Not applicable Interventional Results available

Effects of Exercise Training and Ketone Ester on Muscle Strength and Cardiovascular Response in Parkinson's Disease

NCT05948956
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ketone Ester Beverage, Electrolyte Beverage, Cycling Intervention
Dietary Supplement · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
45 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitrous Oxide for Pain Management During In-office Transcervical Sterilization

NCT02312739
View directory record Official record
Conditions
Contraception, Inhalation of Nitrous Oxide
Interventions
In-office Transcervical Sterilization (Essure®), Standard Oral pain medications, Intramuscular Ketorolac, Placebo pills, Oxygen, Nitrous Oxide
Procedure · Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
21 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Caffeine/Propranolol Intervention for Acute Migraine

NCT01080677
View directory record Official record
Conditions
Migraine Disorders
Interventions
caffeine/propranolol combination tablet, placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240630
View directory record Official record
Conditions
Migraine Disorders, Migraine
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
50
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 29, 2026, 10:59 PM EDT
Completed Not applicable Interventional Results available

Translating an Efficacious Illness Management Intervention for Youth With Asthma

NCT03317977
View directory record Official record
Conditions
Asthma in Children
Interventions
Reach for Control, MATCH
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
12 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 29, 2026, 10:59 PM EDT